Do you have the same question? Follow this Question
Jun 11, 2026 - 08:26 AM
We’ve provided several answers to questions related to Simponi (Golimumab) , see some other helpful Q&A related to this product.
Question: What class of drug does this medication belong to?
Answer: It is a TNF blocker, which means it inhibits tumor necrosis factor, a substance involved in inflammation. TNF blockers are valuable in treating autoimmune diseases because they specifically target and reduce inflammatory processes.
Question: When was this medication approved by the US FDA?
Answer: It was approved by the US Food and Drug Administration (FDA) in 2009. FDA approval confirms the drug’s safety and efficacy for its intended uses.
Question: What is the dosing schedule for ulcerative colitis?
Answer: For ulcerative colitis, the initial dose is 200 mg, followed by 100 mg at week two, then 100 mg every four weeks for maintenance. This induction and maintenance approach helps rapidly control symptoms and then maintain remission.
Question: What are the common side effects of golimumab?
Answer: Common side effects of golimumab include upper respiratory infections, injection site reactions, and headache. Some people may also experience nausea, high blood pressure, or increased liver enzymes. Serious side effects, though less common, can include infections and allergic reactions.
